NCT07141810View on ClinicalTrials.gov

Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

May 30, 2028

Conditions
Fibrotic Interstitial Lung Disease
Interventions
DRUG

Antifibrotic drugs (nidanib or pirfenidone)

One group received primary therapy, and another group received an antifibrotic drug (nidanib or pirfenidone) in addition to primary therapy.

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER